Reviewer's report
Title:Treatment with Pirfenidone for two years decreases fibrosis, cytokine levels
and enhances CB2 expression in patients with chronic hepatitis C: open-label
clinical trial
Version:5Date:22 June 2014
Reviewer: lawrence serfaty
Reviewer's report:
This paper has been improved.
In the last part of discussion, cost of DAAs in developing countries should be
highlighted rather than their supposed low efficacy in G1/G2 infected patients
(SVR rate >90% with sofosbuvir).
Pirfenidone could also be evaluated in other chronic liver disease.
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
No
Reviewer's report
Title:Treatment with Pirfenidone for two years decreases fibrosis, cytokine levels
and enhances CB2 expression in patients with chronic hepatitis C: open-label
clinical trial
Version:5Date:22 June 2014
Reviewer: lawrence serfaty
Reviewer's report:
This paper has been improved.
In the last part of discussion, cost of DAAs in developing countries should be
highlighted rather than their supposed low efficacy in G1/G2 infected patients
(SVR rate >90% with sofosbuvir).
Pirfenidone could also be evaluated in other chronic liver disease.
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
No
Please review this paper.
user
Reviewer's report
Title:Treatment with Pirfenidone for two years decreases fibrosis, cytokine levels
and enhances CB2 expression in patients with chronic hepatitis C: open-label
clinical trial
Version:5Date:22 June 2014
Reviewer: lawrence serfaty
Reviewer's report:
This paper has been improved.
In the last part of discussion, cost of DAAs in developing countries should be
highlighted rather than their supposed low efficacy in G1/G2 infected patients
(SVR rate >90% with sofosbuvir).
Pirfenidone could also be evaluated in other chronic liver disease.
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
No
assistant